Sambio officially secured reimbursement listing for Akugo\ud83c\udd2c Brain Transplant Injection on May 20, 2026, and is promoting clinical trials and global expansion. It obtained manufacturing and sales approval in July 2024 and plans to begin initial shipments from August 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4592","jir_company_name":"Sambio Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4592-20260520-01.pdf","jir_short_summary":"Sambio officially secured reimbursement listing for Akugo\ud83c\udd2c Brain Transplant Injection on May 20, 2026, and is promoting clinical trials and global expansion. It obtained manufacturing and sales approval in July 2024 and plans to begin initial shipments from August 2026.","jir_summary":"### Performance Overview\nSambio officially secured reimbursement listing for Akugo\ud83c\udd2c Brain Transplant Injection on May 20, 2026, and obtained manufacturing and sales approval on July 31, 2024. It plans to advance clinical trials and gradually introduce the product to medical institutions. Initial shipments are scheduled from August 2026 to January 2027, with a focus on global expansion and broadened indications.\n\n### Future Outlook and Strategies\nSambio is progressing clinical trials of Akugo\ud83c\udd2c primarily through medical institutions, building a healthcare collaboration system that considers patient administration and rehabilitation. In the United States, preparations for phase 3 trials are underway, with plans to expand indications to include stroke and other conditions. The company is actively pursuing medium- to long-term growth opportunities.","jir_financial_highlights":"Reimbursement Amount: 72,716,528 yen (Unknown)\nManufacturing and Sales Approval Date: July 31, 2024 (Unknown)\nPreparation for Clinical Trials: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Sambio, #IRRelated, #JapanStocks","jir_key_figures":"Reimbursement amount: 72,716,528 yen\nManufacturing and sales approval date: July 31, 2024\nPreparation for clinical trials: Unknown","jir_meta_title":"\u3010Sambio\u3011Reimbursement Listing and Future Outlook of Akugo Brain Transplant Injection\uff5cMay 2026","jir_meta_description":"Sambio confirmed the reimbursement listing of Akugo\ud83c\udd2c in May 2026 and is promoting clinical trials and global expansion. Approval was obtained in 2024, with initial shipments scheduled from 2026 onward.","jir_og_title":"\u3010Sambio\u3011Reimbursement Listing and Future Outlook for Akugo\uff5cMay 2026","jir_og_description":"Sambio confirmed the reimbursement listing of Akugo\ud83c\udd2c in May 2026, advancing clinical trials and global expansion. After approval in 2024, shipments are planned from 2026 onward.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9416,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-53207","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n